Category: SF1
2017
PopularResponses To Antimicrobial Resistance In All Policies – The German AMR Strategy
Karin Knufmann-Happe, Director General For Health Protection, Disease Control and Biomedicine, Federal Ministry of Health, Germany In 2015, the German Antibiotic Resistance Strategy, DART 2020, was approved by the Federal...
Economics and Innovation
LatestThe Economics of reducing antibiotic use to reduce antimicrobial resistance
Dr Edward I Broughton Director of Research and Evaluation, Q&P Institute, USAID ASSIST URC, USA Human consumption of antibiotics is only beneficial to societal welfare when the correct antibiotics are used and they are given...
2017
Healthcare
PopularDrug-Resistant Tuberculosis: What Is The Situation, What Are The Needs To Roll It Back?
Dr Karin Weyer, Coordinator, Laboratories, Diagnostics and Drug Resistance; Dr Dennis Falzon, Medical Officer; Dr Ernesto Jaramillo, Team Leader, Drug-Resistant TB Policies; Dr Matteo Zignol, Team Lead, Global Project on...
Economics and Innovation
Top RatedThe role of the biomedical advanced research and development authority (BARDA) in promoting innovation in antibacterial product development
Dr Christopher Houchens, Branch Chief, Antibacterial Program and Dr Joe Larsen Deputy Director, Division of CBRN Medical Countermeasures, Biomedical Advanced Research and Development Authority, Office of Assistant Secretary for...
All
Latest
Phage therapy: A promising weapon in the global superbug crisis
Phage therapy: A promising weapon in the global superbug crisis Dr Steffanie Strathdee, Associate Dean of Global Health Sciences, Harold Simon Professor of Medicine and Co-Director, Center for Innovative Phage Applications
- All
- Diagnostics
- Rational use of antibiotics
Phage therapy: A promising weapon in the global superbug crisis
Phage therapy: A promising weapon in the global superbug crisis Dr Steffanie Strathdee, Associate Dean of Global Health Sciences, Harold Simon Professor of Medicine and Co-Director, Center for Innovative Phage Applications
Augmented* medicine for all
Fabienne Ostermeyer, International Development Director, Visiomed Group International Imagine if...
The evolution of the global antibiotic resistance partnership
Hellen Gelband, Associate Director for Policy, Center for Disease Dynamics, Economics & Policy...
Global Health Dynamics
Cancer Control
